Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) Patents (Class 424/184.1)
  • Patent number: 10653763
    Abstract: The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is F. psychrophilum and/or infectious pancreatic necrosis virus (IPNV).
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: May 19, 2020
    Assignee: BENCHMARK ANIMAL HEALTH LIMITED
    Inventors: Elizabeth Mary Crump, Jan Burian, Joseph Michale Bricker, William Wayne Kay, Norman William Johnson
  • Patent number: 10653764
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: May 19, 2020
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Patent number: 10653771
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: May 19, 2020
    Assignee: GENOCEA BIOSCIENCES, INC.
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne, George R. Siber
  • Patent number: 10646460
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting growth of cancer stem cells, containing an aldehyde inhibitor and a biguanide-based compound. The pharmaceutical composition according to the present invention contains a combination of an aldehyde inhibitor and a biguanide-based compound, which can effectively inhibit the growth of cancer stem cells such as neurospheres and can also inhibit the proliferation, invasion and metastasis of cancer cells, thereby preventing and/or treating cancer such as brain cancer.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: May 12, 2020
    Assignee: National Cancer Center
    Inventors: Seok Gu Kang, Jong Hee Chang, Eui Hyun Kim, Ji Hyun Lee, Yun Hee Jo, Junseong Park, Jin Kyoung Shim, Soo Youl Kim
  • Patent number: 10646442
    Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a drug in a dissolved state, an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase, and a release rate of the drug from each of the liposomes is 10%/24 hr to 70%/24 hr in blood plasma at 37° C.; and a method for producing the same.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: May 12, 2020
    Assignee: FUJIFILM Corporation
    Inventors: Takeshi Matsumoto, Kohei Ono, Makoto Ono, Kyoko Senga
  • Patent number: 10641770
    Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic reagents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: May 5, 2020
    Assignee: Statens Serum Institut
    Inventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
  • Patent number: 10638784
    Abstract: The present invention provides a pharmaceutical composition and a food product for inhibiting gastritis induced by gastric Helicobacter pylori, comprising Lactobacillus selected from a group composed of Lactobacillus rhamnosus GM-020 (also known as GMNL-74) with deposited number CCTCC M203098; Lactobacillus acidophilus GMNL-185 with deposited number CCTCC M2017764; and Lactobacillus plantarum GMNL-662 with deposited number CCTCC M2016571; and any two of the above bacteria.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: May 5, 2020
    Assignee: GENMONT BIOTECH INCORPORATION
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Ya-Hui Chen, Chih-Ho Lai, Yu-Hsin Lin
  • Patent number: 10639355
    Abstract: The invention provides a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27° C. under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 5, 2020
    Assignee: QUARRYMEN & Co. Inc.
    Inventor: Minoru Ueda
  • Patent number: 10639361
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: May 5, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine Marchand
  • Patent number: 10626414
    Abstract: The present invention relates to Equine Herpes Virus (EHV) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably ORF70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof. Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition comprising embodiments of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 21, 2020
    Inventors: Andreas Gallei, Alice Mundt, Veljko Nikolin
  • Patent number: 10619169
    Abstract: The present invention relates to the field of (vector) vaccines, and especially to the novel EHV insertion site ORF70. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 14, 2020
    Inventors: Alice Mundt, Andreas Gallei, Kristina Rehmet
  • Patent number: 10611835
    Abstract: An antibody or a fragment thereof having immunoreactivity to a polypeptide comprising not less than 7 continuous amino acids in the CD179b protein, which was identified as a cancer antigen protein specifically expressed on the surfaces of cancer cells, can be used as a pharmaceutical composition for therapy and/or prophylaxis of cancer.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: April 7, 2020
    Assignee: Toray Industries, Inc.
    Inventors: Fumiyoshi Okano, Takanori Saito, Takayoshi Ido, Masaki Shimizu
  • Patent number: 10612032
    Abstract: Inducible promoters for the coordinated expression of at least one heterologous gene in yeast and methods of using them are disclosed. In particular, the invention relates to sets of inducible promoters derived from S. cerevisiae and related species that can be induced in the presence of nonfermentable carbon sources.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: April 7, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Colin Harvey, Ulrich Schlecht, Maureen Elizabeth Hillenmeyer
  • Patent number: 10603210
    Abstract: A method of improving meibomian gland function in a patient includes inserting a cannula into an interior of a meibomian gland of the patient through an orifice thereinto, the cannula including at least one opening in communication with the interior of the meibomian gland, and injecting a blood product into the interior of the meibomian gland through the inserted cannula via the at least one opening.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 31, 2020
    Assignee: MGD INNOVATIONS, LLC
    Inventor: Steven L. Maskin
  • Patent number: 10603353
    Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 31, 2020
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Jürgen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
  • Patent number: 10604793
    Abstract: A cleavage-based real-time PCR assay method is provided. In general terms, the assay method includes subjecting a reaction mixture comprising a) PCR reagents for amplifying a nucleic acid target, and b) flap cleavage reagents for performing a flap cleavage assay on the amplified nucleic acid target to two sets of thermocycling conditions. No additional reagents are added to the reaction between said first and second sets of cycles and, in each cycle of the second set of cycles, cleavage of a flap probe is measured.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: March 31, 2020
    Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLC
    Inventors: Rebecca Oldham-Haltom, Hongzhi Zou, Graham P. Lidgard, Michael J. Domanico, Hatim Allawi
  • Patent number: 10596250
    Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: March 24, 2020
    Assignee: Longhorn Vaccines and Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Patent number: 10597663
    Abstract: There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, and RRSP). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9. Associated nucleic acids, pharmaceutical compositions, methods, uses, and kits are also described, including those of therapeutic significance aimed at treating diseases or disorders caused by enzyme or protein deficiency.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: March 24, 2020
    Assignee: THE HOSPITAL FOR SICK CHILDREN
    Inventors: Roman A. Melnyk, Anick Auger, Greg Beilhartz, Berge Minassian, Seiji Sugiman-Marangos
  • Patent number: 10596248
    Abstract: Disclosed are therapeutic compositions and methods for inducing an immune response to human papillomavirus (HPV). More particularly, disclosed is a method for inducing an immune response in a subject by introducing and expressing a nucleic acid molecule encoding an immunogenic HPV antigen.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 24, 2020
    Assignee: Jingang Medicine (Australia) Pty Ltd
    Inventors: Julie Dutton, Ian Frazer
  • Patent number: 10597606
    Abstract: A method for producing monovalent unsaturated free fatty acids having 20 and/or 22 carbons or low-grade alcohol esters thereof, said method involving the following: obtaining free fatty acids or low-grade alcohol esters through the hydrolysis or alcoholysis of oils and fats derived from marine products; carrying out distillation on the free fatty acids or low-grade alcohol esters, and reducing the concentration of fatty acids with 18 or less carbons in the low-grade alcohol esters or free fatty acids; and collecting fractions of monovalent unsaturated free fatty acids having 20 and/or 22 carbons or low-grade alcohol esters thereof by column chromatography based on reversed-phase distribution.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 24, 2020
    Assignee: Nippon Suisan Kaisha, Ltd.
    Inventors: Seizo Sato, Takuro Fukae, Naomi Ohtsuka, Hideaki Yamaguchi
  • Patent number: 10588986
    Abstract: The present invention relates to biofunctionalized nanoparticles and uses thereof in adoptive cell therapy. In particular, the present invention relates to a nanoparticle comprising an amount of at least one antigen and an amount of at least one antibody having specificity for a B cell receptor wherein the antigen and antibody are attached to the surface of the nanoparticle.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: March 17, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ENS-ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD-LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), HOSPICE CIVILS DE LYON
    Inventors: Antoine Sicard, Olivier Thaunat
  • Patent number: 10588952
    Abstract: The present invention provides a compound represented by the formula (1): wherein Xa and Ya are each a single bond or the like, cancer antigen peptide A is an MHC class I-restricted cancer antigen peptide, and R1 is a hydrogen atom; a group represented by the formula (2): wherein Xb and Yb are each a single bond or the like, and cancer antigen peptide B is different from the cancer antigen peptide A and is an MHC class I or II-restricted cancer antigen peptide; a group represented by the formula (3): wherein Xc and Yc are each a single bond or the like, and cancer antigen peptide C is an MHC class II-restricted cancer antigen peptide; or cancer antigen peptide D, wherein the cancer antigen peptide D is an MHC class I or II-restricted cancer antigen peptide containing one cysteine residue, or a salt thereof, for example.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: March 17, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Yosuke Takanashi
  • Patent number: 10590182
    Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Wendell A. Lim, Leonardo Morsut, Kole T. Roybal, Justin Thomas Farlow, Satoshi Toda
  • Patent number: 10583184
    Abstract: The invention provides a bioactive peptide including a partial amino acid sequence of Plasmodium falciparum enolase, and having a molecular structure compatible with a specification setting for a GMP-compliant production process. The peptide has a structure in which two peptides, each having an amino acid sequence of A01-Ala-Ser-Glu-Phe-Tyr-Asn-Ser-Glu-Asn-Lys-Thr-Tyr-Asp-Leu-Asp-Phe-Lys-Thr-Pro-Asn-Asn-Asp-A02 (SEQ ID NO: 1) or A03-Ala-Ser-Glu-Phe-Tyr-Asn-Ser-Glu-Asn-Lys-Thr-Tyr-Asp-Leu-Asp-Phe-Lys-Thr-Pro-Asn-Asn-Asp-Lys-Ser-Leu-Val-Lys-Thr-A04 (SEQ ID NO: 2) are linked by amide bonds between the respective carboxy termini of the two peptides and two amino groups of Lys in a linker peptide represented by Lys-A05-Cys-A06 and arranged in the form of a two-forked branch, wherein each of A01 to A06 represents an amino acid residue in a number of an arbitrary number including 0.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: March 10, 2020
    Inventor: Shigeyuki Kano
  • Patent number: 10576144
    Abstract: The present invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: March 3, 2020
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Margaret Anne Brimble, Thomas Hugh Wright, Peter Roderick Dunbar, Geoffrey Martyn Williams
  • Patent number: 10576034
    Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: March 3, 2020
    Assignee: University of Massachusetts Lowell
    Inventors: Jonathan Edelson, Robert Nicolosi
  • Patent number: 10577617
    Abstract: The impact of plastid size change in both monocot and dicot plants has been examined. In both, when plastid size is increased there is an increase in biomass relative to the parental lines. Thus, provided herein are methods for increasing the biomass of a plant, comprising decreasing the expression of at least one plastid division protein in a plant. Optionally, the level of chlorophyll in the plant is also reduced.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: March 3, 2020
    Assignees: The Board of Trustees of the University of Illinois, The United States of America, as Represented by the Secretary of Agriculture, The Board of Regents of the University of Nebraska, The University of Florida Research Foundation, Incorporated
    Inventors: Aleel K. Grennan, Donald R. Ort, Stephen Patrick Moose, Damla D. Bilgin, Thomas Clemente, Fredy Altpeter, Stephen P. Long
  • Patent number: 10577409
    Abstract: The present invention relates to a monoclonal antibody that inhibits immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody. The monoclonal antibody or antigen-binding fragment thereof bind to a peptide consisting an amino acid sequence represented by MEKVGKDGVITVE (SEQ ID NO: 1). The present invention also discloses use of the invented monoclonal antibody or antigen-binding fragment thereof, and method of preparation for such hybridomas.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 3, 2020
    Assignee: SAGABIO CO., LTD.
    Inventors: Kuang-Wen Liao, Yu-Ling Lin, Ting-Yan Jian
  • Patent number: 10561724
    Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
  • Patent number: 10561604
    Abstract: Solid and liquid pharmaceutical compositions comprising botulinum neurotoxin complex or high purity botulinum neurotoxin and a surfactant. The composition may comprise a crystalline agent.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: February 18, 2020
    Assignee: IPSEN BIOPHARM LIMITED
    Inventors: Paul Webb, Mary White, Julie Partington
  • Patent number: 10561725
    Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: February 18, 2020
    Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Barton F. Haynes, Hua-Xin Liao, Li-Hua Ping, Ronald Swanstrom, Beatrice H. Hahn, George M. Shaw
  • Patent number: 10561703
    Abstract: Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence identity of at least 80% with SEQ ID NO: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: February 18, 2020
    Assignee: GemVaX & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10561719
    Abstract: The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: February 18, 2020
    Assignee: Vaxiion Therapeautics, LLC
    Inventor: Matthew J. Giacalone
  • Patent number: 10548966
    Abstract: The present invention relates to compositions and methods for the treatment and prevention of canine influenza virus (CIV) and CIV-related pathology. The present invention is based in part upon the discovery that one or more mutations in segment 4 of the viral genome produces a single cycle infectious CIV (sciCIV). The sciCIV does not allow for the production of infectious progeny, but is able to induce a CIV-specific immune response.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: February 4, 2020
    Assignees: UNIVERSITY OF ROCHESTER, CORNELL UNIVERSITY
    Inventors: Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Colin Parrish
  • Patent number: 10543239
    Abstract: The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: January 28, 2020
    Assignee: DuPont Nutrition Biosciences ApS
    Inventors: Remy Burcelin, Didier Carcano, Pierre Desreumaux, Sampo Lahtinen, Nina Rautonen, Heli Putaala, Kirsti Tiihonen, Rodolphe Barrangou
  • Patent number: 10544462
    Abstract: The present invention relates generally to the identification of subjects with a predisposition to recurrent depression, predicting a subject's responsiveness to therapy, and determining whether a subject has remitted from depression following therapy. In particular, provided herein are biomarkers, methods, and kits for such uses.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 28, 2020
    Assignee: NORTHWESTERN UNIVERSITY
    Inventor: Eva E. Redei
  • Patent number: 10537607
    Abstract: Provided herein are novel compositions, specifically, caveolin modulators, and methods to treat and/or prevent autoimmune and/or inflammatory diseases/conditions using such compositions.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: January 21, 2020
    Assignee: E&B Technologies LLC
    Inventors: David Eveleth, William C. Sessa
  • Patent number: 10533034
    Abstract: Glycosphingolipids (GSLs) compositions and methods for iNKT-independent induction of chemokines are disclosed.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 14, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Alice L. Yu, Kun-Hsien Lin, Tai-Na Wu
  • Patent number: 10532019
    Abstract: The embodiment described herein are related nanoemulsions comprising botulinum toxins. In one embodiment, the nanoemulsions are prepared by high pressure microfluidization and comprise a particle size distribution exclusively between 10 and 300 nm. The nanoemulsions contemplated by the present invention are useful for the cosmetic and medical treatment of muscular contracture states. For example, botulinum toxin may relax facial muscles such that skin wrinkles become smoother and less noticeable. Further, the present invention contemplates a cosmetic formulation that may be self-administered, for example, in the privacy of one's home and without medical supervision.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: January 14, 2020
    Assignee: University of Massachusetts Lowell
    Inventors: Jonathan Edelson, Robert Nicolosi
  • Patent number: 10532090
    Abstract: The present invention provides a vaccine composition comprising: (i) an adjuvant; and (ii) at least one fusion peptide conjugated to a carrier protein, wherein the carrier protein is the diphtheria toxin variant CRM-197 (GenBank Accession No. 1007216A) and wherein the at least one fusion peptide comprises two or more non-contiguous B cell epitopes of Her2/neu selected from the group consisting of SEQ ID Nos:1-7 and 15-60 and amino acid sequences that have at least 85% identity to any of the foregoing. The present invention also extends to pharmaceutical compositions and methods of using the vaccine and/or pharmaceutical compositions, as herein described, for the treatment or prevention of a cancer characterised by the expression or over-expression of Her2/neu in a patient in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 14, 2020
    Assignee: Biolife Science QLD Limited
    Inventor: Ursula Wiedermann
  • Patent number: 10526379
    Abstract: A method of producing a fusion protein is provided. The method includes: a) contacting a first protein with a second protein under conditions that enable the formation of an isopeptide bond between said proteins to form a linked protein; and b) contacting the linked protein from (a) with a third protein under conditions that enable the formation of an isopeptide bond between said third protein and said linked protein to form a fusion protein. Peptide linkers and the use of orthogonal pairs of said linkers in the synthesis of fusion proteins are also provided. Recombinant proteins comprising said linkers, nucleic acid molecules encoding said proteins and linkers, vectors comprising said nucleic acid molecules and host cells comprising said vectors and nucleic acid molecules are also contemplated.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: January 7, 2020
    Assignee: Oxford University Innovation Limited
    Inventor: Mark Howarth
  • Patent number: 10526392
    Abstract: A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: January 7, 2020
    Assignee: 1GLOBE BIOMEDICAL CO., LTD.
    Inventors: Chiang J. Li, Shyam Unniraman
  • Patent number: 10517939
    Abstract: The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: A. providing a bacterial strain capable of expressing glutamate racemase and possibly D-amino acid transaminase and comprising a peptidoglycan cell wail, and B. inactivating the gene or genes encoding for the glutamate racemase enzyme and, if needed, the gene or genes encoding for the enzyme D-amino acid transaminase in such way that the bacterial strain is no longer capable of expressing a functional glutamate racemase and/or a functional D-amino acid transaminase; wherein the inactivation of said genes causes said bacterial strain to be auxotrophic for D-glutamate.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: December 31, 2019
    Assignees: SERVICIO GALEGO DE SAÚDE (SERGAS), FUNDACIÓN PROFESOR NOVOA SANTOS
    Inventors: Germán Bou Arévalo, María Clara Póvoa Cabral, Astrid Pérez Gómez, María Merino Carballeira, Alejandro Beceiro Casas, Patricia García Fernández
  • Patent number: 10499642
    Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, and their uses as insecticides.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: December 10, 2019
    Assignee: Syngenta Participations AG
    Inventors: Anthony Cornelius O'Sullivan, Myriem El Qacemi, Jérôme Yves Cassayre, Thomas Pitterna, André Stoller
  • Patent number: 10500260
    Abstract: Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. The method for screening an allograft recipient (including pregnant women) for chronic allograft rejection comprises the steps of measuring an amount of a natural antibody within a biological sample and comparing the amount of the first natural antibody with the amount of the first natural antibody present within a control sample; wherein a decrease in the amount of the first natural antibody as compared to those levels seen in the control indicates a diagnosis of being at-risk for or experiencing chronic allograft rejection. Furthermore, in an embodiment of a composition for preventing or treating chronic allograft rejection, the composition comprises a therapeutically effective amount of phosphorylcholine sufficient to initiate the production of anti-phosphorylcholine natural antibodies in a mammal following administration thereto.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: December 10, 2019
    Assignee: 3DT Holdings, LLC
    Inventors: Ghassan S. Kassab, Carlos A. Labarrere
  • Patent number: 10501782
    Abstract: The present invention relates to an improved process for synthesis of DNA, RNA, proteins and like molecules, in particular cell-free enzymatic synthesis of DNA, preferably in large scale. The present invention relates to the synthesis of DNA using strand-displacement replication and the addition of nucleotides to the reaction mixture is controlled, thus controlling yield. The reaction mixture contains a starting amount of nucleotides, polymerase and DNA template, to which further nucleotides are supplied in a controlled manner.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: December 10, 2019
    Assignee: Touchlight IP Limited
    Inventors: Neil Porter, Paul Rothwell, Jonathan Extance
  • Patent number: 10494422
    Abstract: The present application generally relates to methods of genetically modifying a T-cell comprising a chimeric antigen receptor wherein the T-cell lacks a co-receptor for HIV. The application further relates to methods of making a nucleic acid encoding a chimeric antigen receptor, nucleic acids encoding a chimeric antigen receptor, and genetically modified T-cells comprising a chimeric antigen receptor disclosed herein. The application further relates to methods of treating, inhibiting, or ameliorating HIV in a subject including administering to the subject a cell disclosed herein.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: December 3, 2019
    Assignee: Seattle Children's Hospital
    Inventors: Thor Wagner, Andrew M. Scharenberg, David J. Rawlings, Blythe Sather, Jaya Sahni
  • Patent number: 10494414
    Abstract: The objective of the present invention is to provide a peptide of which both of binding forces to a Fc region and a Fab region are superior. In addition, the objective of the present invention is to provide a DNA which encodes the peptide, a vector which contains the DNA, and a transformant which is transformed by the vector. The problem can be solved by providing the peptide having the specific sequence.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: December 3, 2019
    Assignee: KANEKA CORPORATION
    Inventors: Shinichi Yoshida, Dai Murata
  • Patent number: 10485857
    Abstract: The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i.e., the amino acid or protein sequence) of the target sequence. After introduction of the vaccine composition containing the target antigen into the host (e.g., a canine), the host will generate antibodies as part of its robust immune response to the antigen. As the antibodies circulate through the host's plasma, heartworm larvae will consume the antibodies as they feed on the plasma. The antibodies will then act on internal targets of the worm recognized as antigens.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: November 26, 2019
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Laurent Fischer, Yovany Moreno, Cecile Sigoillot-Claude, Frederic Beugnet
  • Patent number: 10485865
    Abstract: The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 26, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Gerald Hermann Voss